Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.12 -1.4%	$1.53	$1.11 ▼ $5.00	$564.22M	1.76	1.79 million shs	1.89 million shs
BCAX Bicara Therapeutics	$10.84 -6.3%	$12.37	$7.80 ▼ $28.09	$591.17M	N/A	583,375 shs	443,111 shs
EOLS Evolus	$9.93 -2.5%	$10.30	$8.67 ▼ $17.82	$640.25M	1	738,558 shs	1.07 million shs
RAPT RAPT Therapeutics	$1.04 -4.6%	$0.92	$0.71 ▼ $3.83	$137.58M	-0.11	1.28 million shs	617,861 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-4.02%	-4.87%	+69.29%	+14.97%	-50.46%
BCAX Bicara Therapeutics	-2.61%	+4.90%	-11.27%	-6.84%	+1,156,999,900.00%
EOLS Evolus	-0.59%	+4.52%	+0.49%	-22.88%	-11.71%
RAPT RAPT Therapeutics	-0.91%	+6.86%	+45.74%	-4.39%	-69.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.572 of 5 stars	3.5	1.0	0.0	2.6	3.3	0.6
BCAX Bicara Therapeutics	2.2976 of 5 stars	3.5	0.0	0.0	3.4	0.8	0.6
EOLS Evolus	4.0782 of 5 stars	3.5	1.0	3.5	2.9	3.3	0.6
RAPT RAPT Therapeutics	4.024 of 5 stars	3.2	1.0	4.2	3.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	339.62% Upside
BCAX Bicara Therapeutics	3.00	Buy	$31.86	193.90% Upside
EOLS Evolus	3.00	Buy	$23.75	139.17% Upside
RAPT RAPT Therapeutics	2.33	Hold	$3.00	188.46% Upside

Current Analyst Ratings Breakdown

Latest RAPT, BCAX, AUTL, and EOLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/22/2025	RAPT RAPT Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$2.00 ➝ $1.00
5/22/2025	RAPT RAPT Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$6.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/10/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$9.01M	62.61	N/A	N/A	$0.64 per share	3.31
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	$275.46M	2.32	N/A	N/A	($0.36) per share	-27.58
RAPT RAPT Therapeutics	$1.53M	89.92	N/A	N/A	$4.27 per share	0.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$0.88	N/A	N/A	N/A	N/A	-63.65%	-36.54%	8/14/2025 (Estimated)
BCAX Bicara Therapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
EOLS Evolus	-$61.69M	-$0.89	N/A	N/A	N/A	-22.33%	-847.60%	-22.15%	7/30/2025 (Estimated)
RAPT RAPT Therapeutics	-$116.80M	-$2.40	N/A	N/A	N/A	N/A	-89.10%	-76.13%	8/6/2025 (Estimated)

Latest RAPT, BCAX, AUTL, and EOLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	RAPT RAPT Therapeutics	-$0.31	-$0.08	+$0.23	-$0.08	N/A	N/A
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A
3/20/2025	Q4 2024	AUTL Autolus Therapeutics	-$0.21	-$0.09	+$0.12	-$0.09	$2.98 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
RAPT RAPT Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
BCAX Bicara Therapeutics	N/A	N/A	N/A
EOLS Evolus	20.58	2.47	2.23
RAPT RAPT Therapeutics	N/A	9.90	9.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
BCAX Bicara Therapeutics	N/A
EOLS Evolus	90.69%
RAPT RAPT Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
BCAX Bicara Therapeutics	15.50%
EOLS Evolus	5.90%
RAPT RAPT Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.71 million	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
EOLS Evolus	170	64.48 million	59.46 million	Optionable
RAPT RAPT Therapeutics	80	132.29 million	32.65 million	Optionable

RAPT, BCAX, AUTL, and EOLS Headlines

Recent News About These Companies

RAPT Therapeutics, Inc.: RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13 at 1:15 PM | finanznachrichten.de

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13 at 9:00 AM | globenewswire.com

Two Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

June 12 at 3:27 AM | marketbeat.com

Clear Street initiates Rapt Therapeutics stock with buy rating

June 7, 2025 | uk.investing.com

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position

June 6, 2025 | msn.com

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $3.00 Consensus PT from Analysts

June 6, 2025 | americanbankingnews.com

Rapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA hold

June 4, 2025 | fiercebiotech.com

RAPT Therapeutics to Participate in Upcoming Investor Conferences

June 4, 2025 | globenewswire.com

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Brokerages

June 3, 2025 | marketbeat.com

Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%

June 2, 2025 | marketbeat.com

What is HC Wainwright's Forecast for RAPT Q2 Earnings?

May 27, 2025 | marketbeat.com

12 Health Care Stocks Moving In Friday's Intraday Session

May 25, 2025 | benzinga.com

RAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street Zen

May 24, 2025 | marketbeat.com

UBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock Price

May 24, 2025 | marketbeat.com

RAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC Wainwright

May 24, 2025 | marketbeat.com

11,764,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by RTW Investments LP

May 18, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

May 16, 2025 | zacks.com

13,135,260 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Orbimed Advisors LLC

May 15, 2025 | marketbeat.com

RAPT Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Why RAPT Therapeutics, Inc.’s (RAPT) Stock Is Down 5.55%

May 8, 2025 | aaii.com

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

April 18, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, BCAX, AUTL, and EOLS Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.12 -0.03 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 04:29 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Bicara Therapeutics NASDAQ:BCAX

$10.84 -0.73 (-6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$10.84 +0.01 (+0.05%)

As of 04:04 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Evolus NASDAQ:EOLS

$9.93 -0.25 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$9.94 +0.02 (+0.15%)

As of 04:09 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

RAPT Therapeutics NASDAQ:RAPT

$1.04 -0.05 (-4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 0.00 (-0.10%)

As of 04:37 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time